WO1999011282A1 - Compositions and methods for contraception in or sterilization of mammals - Google Patents
Compositions and methods for contraception in or sterilization of mammals Download PDFInfo
- Publication number
- WO1999011282A1 WO1999011282A1 PCT/US1998/018117 US9818117W WO9911282A1 WO 1999011282 A1 WO1999011282 A1 WO 1999011282A1 US 9818117 W US9818117 W US 9818117W WO 9911282 A1 WO9911282 A1 WO 9911282A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lps
- mastoparan
- septic shock
- protein
- agent
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 22
- 239000000203 mixture Substances 0.000 title claims description 18
- 241000124008 Mammalia Species 0.000 title abstract description 4
- 230000001954 sterilising effect Effects 0.000 title abstract 2
- 238000004659 sterilization and disinfection Methods 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 28
- 206010040070 Septic Shock Diseases 0.000 claims description 70
- 108091006027 G proteins Proteins 0.000 claims description 68
- 102000030782 GTP binding Human genes 0.000 claims description 68
- 108091000058 GTP-Binding Proteins 0.000 claims description 68
- MASXKPLGZRMBJF-MVSGICTGSA-N mastoparan Chemical group CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(N)=O MASXKPLGZRMBJF-MVSGICTGSA-N 0.000 claims description 60
- 108010019084 mastoparan Proteins 0.000 claims description 60
- 230000036303 septic shock Effects 0.000 claims description 60
- 239000003795 chemical substances by application Substances 0.000 claims description 52
- 206010014824 Endotoxic shock Diseases 0.000 claims description 9
- 239000003242 anti bacterial agent Substances 0.000 claims description 8
- 241000894006 Bacteria Species 0.000 claims description 6
- 230000003115 biocidal effect Effects 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 241000192125 Firmicutes Species 0.000 claims description 3
- 230000035939 shock Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 37
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 9
- 238000001727 in vivo Methods 0.000 abstract description 6
- 239000000556 agonist Substances 0.000 abstract description 5
- 230000009089 cytolysis Effects 0.000 abstract description 4
- 210000000170 cell membrane Anatomy 0.000 abstract description 3
- 150000001875 compounds Chemical class 0.000 abstract description 2
- 230000002101 lytic effect Effects 0.000 abstract 5
- 239000003446 ligand Substances 0.000 abstract 4
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 abstract 3
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 abstract 3
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 abstract 3
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 abstract 3
- 230000007774 longterm Effects 0.000 abstract 2
- 101710112752 Cytotoxin Proteins 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 231100000599 cytotoxic agent Toxicity 0.000 abstract 1
- 239000002619 cytotoxin Substances 0.000 abstract 1
- 230000004927 fusion Effects 0.000 abstract 1
- 230000036512 infertility Effects 0.000 abstract 1
- 239000002158 endotoxin Substances 0.000 description 78
- 229920006008 lipopolysaccharide Polymers 0.000 description 74
- 210000001616 monocyte Anatomy 0.000 description 37
- 230000000694 effects Effects 0.000 description 25
- 230000016396 cytokine production Effects 0.000 description 19
- 230000019491 signal transduction Effects 0.000 description 17
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 15
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 15
- 108090001005 Interleukin-6 Proteins 0.000 description 14
- 238000011282 treatment Methods 0.000 description 14
- 230000004913 activation Effects 0.000 description 13
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 108091000080 Phosphotransferase Proteins 0.000 description 11
- 102000020233 phosphotransferase Human genes 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 11
- 239000011230 binding agent Substances 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- 108090000695 Cytokines Proteins 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 102000004127 Cytokines Human genes 0.000 description 8
- 102000034345 heterotrimeric G proteins Human genes 0.000 description 8
- 108091006093 heterotrimeric G proteins Proteins 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 7
- 102000043136 MAP kinase family Human genes 0.000 description 7
- 108091054455 MAP kinase family Proteins 0.000 description 7
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 7
- 206010040047 Sepsis Diseases 0.000 description 7
- 238000000021 kinase assay Methods 0.000 description 7
- 210000002540 macrophage Anatomy 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 230000026731 phosphorylation Effects 0.000 description 7
- 238000006366 phosphorylation reaction Methods 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000017306 interleukin-6 production Effects 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 5
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 5
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 5
- 230000005856 abnormality Effects 0.000 description 5
- 229940095074 cyclic amp Drugs 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 231100000517 death Toxicity 0.000 description 5
- 102000009076 src-Family Kinases Human genes 0.000 description 5
- 108010087686 src-Family Kinases Proteins 0.000 description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 208000034486 Multi-organ failure Diseases 0.000 description 4
- 239000000020 Nitrocellulose Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 229930004094 glycosylphosphatidylinositol Natural products 0.000 description 4
- 239000012133 immunoprecipitate Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 239000012139 lysis buffer Substances 0.000 description 4
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 4
- 229920001220 nitrocellulos Polymers 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 230000029058 respiratory gaseous exchange Effects 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 206010053567 Coagulopathies Diseases 0.000 description 3
- 206010061598 Immunodeficiency Diseases 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 229930182816 L-glutamine Natural products 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 102000052508 Lipopolysaccharide-binding protein Human genes 0.000 description 3
- 108010053632 Lipopolysaccharide-binding protein Proteins 0.000 description 3
- 208000010718 Multiple Organ Failure Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000036760 body temperature Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000035602 clotting Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 238000001114 immunoprecipitation Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 231100000518 lethal Toxicity 0.000 description 3
- 230000001665 lethal effect Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 230000002463 transducing effect Effects 0.000 description 3
- 230000006433 tumor necrosis factor production Effects 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 244000187656 Eucalyptus cornuta Species 0.000 description 2
- 102000034353 G alpha subunit Human genes 0.000 description 2
- 108091006099 G alpha subunit Proteins 0.000 description 2
- 108010043685 GPI-Linked Proteins Proteins 0.000 description 2
- 102000002702 GPI-Linked Proteins Human genes 0.000 description 2
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 2
- 108091006109 GTPases Proteins 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 239000012741 Laemmli sample buffer Substances 0.000 description 2
- 108010031801 Lipopolysaccharide Receptors Proteins 0.000 description 2
- 102000005482 Lipopolysaccharide Receptors Human genes 0.000 description 2
- 208000004221 Multiple Trauma Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010033645 Pancreatitis Diseases 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 108060000200 adenylate cyclase Proteins 0.000 description 2
- 102000030621 adenylate cyclase Human genes 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000001010 compromised effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 230000004217 heart function Effects 0.000 description 2
- 230000036543 hypotension Effects 0.000 description 2
- 230000001524 infective effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000008383 multiple organ dysfunction Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- -1 oxygen radicals Chemical class 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- AWAFMFHOLVZLFG-UHFFFAOYSA-N 1-iodoaziridine-2,3-dione Chemical compound IN1C(=O)C1=O AWAFMFHOLVZLFG-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010009192 Circulatory collapse Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 231100000644 Toxic injury Toxicity 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- ZKHQWZAMYRWXGA-KNYAHOBESA-N [[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] dihydroxyphosphoryl hydrogen phosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)O[32P](O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KNYAHOBESA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 201000005008 bacterial sepsis Diseases 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229940046892 lead acetate Drugs 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 235000002867 manganese chloride Nutrition 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000007302 negative regulation of cytokine production Effects 0.000 description 1
- 230000027405 negative regulation of phosphorylation Effects 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000005937 nuclear translocation Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000003836 peripheral circulation Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 108091005981 phosphorylated proteins Proteins 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 206010040560 shock Diseases 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 108091005990 tyrosine-phosphorylated proteins Proteins 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Definitions
- Septic shock also known as sepsis
- sepsis causes more than 150,000 deaths annually in the United States.
- Sepsis is defined as a clinical disorder whose symptoms may include well defined abnormalities in body temperature, heart rate, breathing rate, white blood cell count, hypotension, organ perfusion abnormalities, and multiple organ dysfunction.
- bacterial either gram negative or gram positive
- fungal and viral infections as well as non-infective stimuli such as multiple trauma, severe burns, organ transplantation and pancreatitis.
- endotoxin also referred to herein as lipopolysacchride or LPS
- the major LPS receptor for monocytes/macrophages is the glycosylphosphatidylinositol (GPI) anchored glycoprotein CD 14. It is the interaction of LPS with the LPS receptor CD 14 that initiates the cascade of signaling events that cause cytokine gene transcription. The precise mechanism through which LPS interacts with CD 14 is unknown. Much of the controversy regarding the role of CD 14 in LPS-induced signal transduction and cytokine production stems from the fact that CD 14 is attached to the cell membrane by a glycosylphosphatidylinositol (GPI)-anchor and contains neither transmembrane nor cytoplasmic amino acid sequences.
- GPI glycosylphosphatidylinositol
- CD 14 cannot interact with signal transduction molecules in the same way as transmembrane receptors. Recently, it has been demonstrated that GPI-anchored proteins expressed on many cell types can physically interact with lipid-linked signal transduction molecules, but the functional consequences of these interactions remain unresolved (Stefanova et al., Science, 254: 1016-1018, 1991; Shenoy-Scaria et al., Mol Cell BioL, 13: 6385-6392, 1993; Solomon et al., Proc. Nat. Acad. Sci., 93: 6053-6058, 1996).
- LBP serum factor LPS-binding protein
- monocyte activation by LPS leads to the phosphorylation of p38 mitogen activated protein kinase (MAPK), and production of inflammatory cytokines (i.e., TNF- ⁇ , IL-6) (Sweet, M.J. and Hume D.A., J. Leuk. BioL, 60: 8-26, 1996).
- MAPK mitogen activated protein kinase
- the present invention is based, at least in part, on the discovery that CD 14 on monocytes/macrophages physically interacts with heterotrimeric G proteins and, in particular, that such G proteins specifically regulate LPS-induced mitogen activated protein (MAP) kinase activation and cytokine production in human monocytes/macrophages.
- This invention is further based on the discovery that agents which bind G proteins, such as G protein binding peptides, inhibit G protein signal transduction to thereby treat or prevent septic shock in vivo.
- this invention provides compositions and methods for treating or preventing septic shock in a subject at risk of developing septic shock
- the method comprises administering an effective amount of an agent which binds G protein such that septic shock is treated or prevented in the subject.
- the agents which bind G protein are useful for both proplylactic and/or therapeutic treatments of septic shock.
- the invention also pertains to compositions for treating or preventing septic shock in a subject which include an effective amount of an agent which binds G protein and, optionally, an antibiotic.
- the composition can further include a pharmaceutically acceptable carrier.
- the present invention also provides methods for using agents which bind G proteins in combination with other agents and/or treatment regimens (e.g., antibiotics, intravenous fluids, cardiovascular and respiratory support) to prophylactically and/or therapeutically treat a subject for septic shock.
- agents and/or treatment regimens e.g., antibiotics, intravenous fluids, cardiovascular and respiratory support
- Other aspects of the invention include packaged agents which bind G proteins and instructions for using such agents for treatment of septic shock.
- Figures 1A and IB are gels depicting the association of CD 14 with src kinases and heterotrimeric G proteins.
- Figure 1 A shows that CD 14 is associated with tyrosine phosphorylated proteins.
- Figure IB shows that CD 14 is associated with various src kinases and heterotrimeric G protein ⁇ subunits.
- Figure 2 depicts the inhibition of IL-6 production from LPS-stimulated PMBCs by mastoparan.
- Figure 2 shows that mastoparan but not its inactive analogue (MAS- 17) inhibits LPS-induced cytokine production.
- MAS- 17 inactive analogue
- Figures 3 A and 3B depict the inhibition of cytokine production from LPS- stimulated monocytes by mastoparan.
- Figure 3A shows a dose-dependent inhibition of IL-6 and TNF- ⁇ production in human monocytes by mastoparan.
- Figure 3B shows inhibition of LPS-, but not PMA-, induced cytokine production from human monocytes by mastoparan. The experiments shown are representative of 6 different assays with similar results.
- Figure 4 shows that mastoparan only inhibits CD14-dependent LPS-induced signal transduction in U373-CD14 tranfected cells.
- Figures 5 A and 5B depict the inhibition of phosphorylation of p38 MAP kinase in human monocytes and PMBC by mastoparan.
- Figure 5B shows that mastoparan reduces LPS-induced p38 MAP kinase activity.
- Figure 6 is a gel depicting the effect of LPS and mastoparan on MAP kinase activation in human monocytes.
- Figure 6 shows specific inhibition of LPS-induced Erk kinase activation by mastoparan.
- the present invention pertains to a method for treating or preventing septic shock in a subject by administering to the subject an effective amount of an agent which binds to G protein, such that septic shock in the subject is treated or prevented.
- Septic shock is commonly associated with bacterial infection in a surgical setting or with immunocompromised subjects, and is typically characterized by abnormalities in body temperature, heart rate, blood pressure and breathing which can progress to spontaneous clotting in blood vessels, multiple organ failure and death.
- the present invention also pertains to a composition for treating or preventing septic shock in a subject which includes an effective amount of an agent which binds G protein to treat or prevent septic shock in the subject.
- the composition can further include an antibiotic and/or a pharmaceutically acceptable carrier.
- Septic shock refers to a clinical disorder whose symptoms may include well defined abnormalities in body temperature, heart rate, breathing rate, white blood cell count, hypertension, organ perfusion abnormalities, and multiple organ dysfunction. It may be caused by bacterial (either gram negative or gram positive), fungal, viral or other infection, as well as by non-infective stimuli such as multiple trauma, severe burns, organ transplantation and pancreatitis. Septic shock is commonly caused by "gram-negative" endotoxin-producing aerobic rods —Escherichia coli, Klebsiella pneumoniae, Proteus species, Pseudomonas aeruginosa and Salmonella.
- endotoxic shock Septic shock involved with gram negative bacteria is referred to as "endotoxic shock".
- endotoxin also referred to herein as lipopolysaccharide or "LPS”
- LPS lipopolysaccharide
- the manner in which LPS evokes its effects is by binding to cells such as monocytes/macrophages or endothelial cells and triggering them to produce various mediators, such as oxygen radicals, hydrogen peroxide, tumor necrosis factor-alpha (TNF- ⁇ ), and various interleukins (IL- 1 , IL-6, and IL-8).
- Gram-positive bacteria particularly pneumococcal or streptococcal, may produce a similar clinical syndrome as endotoxic shock.
- endotoxic shock refers to septic shock involved with gram negative and/or gram positive bacteria.
- the septic shock affects the peripheral circulation of a subject.
- the affects of septic shock include direct toxic injury to the subject which may induce arteriolar vasodilation and pooling of blood and elevated capillary pressure leading to the escape of plasma water into the interstitial compartment, further impinging on the circulating blood volume of the subject.
- septic shock leads to an inflammatory-immune reaction which results in the release of vasodilators in the subject, such as histamine and complement fractions, further reducing the effective circulating volume.
- Platelet activation and the formation of thromboxane A2 may add an element of platelet aggregation, with activation of the clotting sequence and the induction of disseminated intravascular coagulation in the subject.
- the overall effect of septic shock in the subject is a decrease in blood volume.
- the language "treat for septic shock" is intended to cover therapeutic and/or prophylactic treatments.
- the agents which bind G proteins can be used to protect a subject from damage on injury caused by septic shock or can therapeutically treat a subject prior to the onset of septic shock.
- agents which bind G protein can treat or reduce the damage or injury caused by septic shock in a subject having one or more symptoms of septic shock.
- Symptoms of septic shock in a subject include tremors, fever, falling blood pressure, rapid breathing, rapid heart beat, and skin lesions. Within hours or days, these symptoms can progress to spontaneous clotting in blood vessels, severe hypotension and multiple organ failure.
- the term "treat” as used herein refers reducing or preventing at least one symptom associated with sepsis. The treatment of a subject need not be complete restoration to the subjects previous state, but rather can be an amount sufficient to prevent mortality of the subject.
- agents which bind G proteins are administered prior to the onset of symptoms of septic shock to prevent or inhibit septic shock in subjects at risk of developing or susceptible to septic shock.
- Subjects at risk of developing septic shock include the elderly, immunocompromised patients (e.g., chemotherapeutic and HIV patients), patients requiring surgery or invasive instrumentation, and patients with compromised cardiac and hepatic function.
- Administering to a subject an agent which binds G protein in these types of settings can be used to decrease the susceptibility of these patients to septic shock.
- subject is intended to include mammals having septic shock, including one or more of the symptoms related to sepsis. Examples of such subjects include humans, dogs, cats, pigs, cows, horses, rats, and mice.
- administering is intended to include routes of administration which allow the agent to perform its intended function of treating or preventing septic shock by binding to G protein.
- routes of administration which can be used include parental injection (e.g., subcutaneous, intravenous, and intramuscular), intraperitoneal injection, oral, inhalation, and transdermal.
- the injection can be bolus injections or can be continuous infusion.
- the agent can be coated with or disposed in a selected material to protect it from natural conditions which may detrimentally effect its ability to perform its intended function.
- the agent is a peptide, such as mastoparan or analog thereof, the peptide can be modified at one or more of its termini to protect the peptide from degradation.
- the agent can be administered with other agents and/or with a pharmaceuticlly acceptable carrier. Further, the agent can be administered as a mixture of agents which bind G proteins, which also can be coadministered with a pharmaceutically acceptable carrier. The agent can be administered prior to the onset of septic shock or after the onset of septic shock.
- pharmaceutically acceptable carrier is intended to include substances capable of being coadministered with the G protein binding agent, and which allows the agent to perform its intended function of treating septic shock or preventing septic shock.
- An example of such a carrier is saline. Any other conventional carrier suitable for use with the G protein binding agent also fall within the scope of the present invention.
- an agent which binds G protein is that amount necessary or sufficient to treat or prevent septic shock, e.g. prevent at least one of the various symptoms of septic shock, or that amount necessary to reduce the pathogenesis of septic shock.
- the effective amount can vary depending on such factors as the size and weight of the subject, the type of illness, the severity of the symptoms, or the particular agent used.
- One of ordinary skill in the art would be able to study the aforementioned factors and make the determination regarding the effective amount of G protein binding agent without undue experimentation.
- G protein binding agents can be administered to the subject either prior to or after the onset of septic shock. Further, several divided dosages, as well as staggered dosages, can be administered daily or sequentially, or the dose can be continuously infused or can be a bolus injection. Further, the dosages of the G protein binding agent(s) can be proportionally increased or decrease as indicated by the exigencies of the therapeutic or prophylactic situation.
- G proteins are important to regulatory mechanisms operating in all human cells. Impairment of their function can perturb the cell's response to hormonal signals and adversely affect many intracellular metabolic pathways, thus contributing to the development and maintenance of a wide variety of disease states.
- G proteins act as an integral part of the signal transducing mechanism by which extracellular hormones and neurotransmitters convey their signals through the plasma membrane of the cell and thus elicit appropriate intracellular responses.
- the signal transducing mechanism of G protein can be said to comprise three distinct components.
- a receptor protein with an extracellular binding site specific for a given agonist a membrane-bound effector protein that when activated catalyzes the formation of facilitates the transport of an intracellular second messenger, an example is adenylate cyclase which produces cyclic AMP (cAMP); and a third protein which functions as a communicator between these two.
- G proteins fulfill this vital role as communicator in the generation of intracellular responses to extracellular hormones and agonists.
- G proteins are composed of three polypeptide subunits, namely G alpha ( ⁇ ), G beta ( ⁇ ), and G gamma ( ⁇ ).
- the binding sites for GTP, GDP and the GTPase catalytic site reside in the ⁇ subunit.
- the G protein cycle which occurs each time a signal is conveyed across the membrane can be summarized as follows: 1) in an unstimulated cell the G proteins are found in the resting state in which ⁇ , ⁇ and ⁇ are complexed together and GDP is bound to G ⁇ , 2) the binding of an appropriate hormone or agonist to the receptor changes its conformation and causes it to activate the G protein by displacing GDP and allowing GTP to bind (this is the rate-limiting step of the G protein cycle), 4) when GTP is bound to G ⁇ it may dissociate from the ⁇ and ⁇ complex and is able to bind to, and activate, adenylate cyclase which releases cAMP into the cytoplasm, 5) GTP is then hydrolysed to GDP and the cycle is complete.
- a further attribute inherent in this system is that it allows several different receptors to interact with a signal-generating enzyme. Some act in such a way to activate the enzyme and some to inhibit it. This involves distinct alpha subunits G sub s alpha (stimulatory) and G sub i alpha (inhibitory) that combine with the same beta gamma complex to form stimulatory or inhibitory G proteins.
- An example of a receptor that interacts with G sub i to lower the concentration of cAMP is the alpha sub 2- adrenergic receptor.
- the integration of the signals from G sub s and G sub i is one of the ways in which the level of cAMP in the cell can be modulated in response to several different extracellular agonists.
- the present invention is based on, at least in part, the demonstration of both a physical and functional coupling of CD 14 to G proteins and the involvement of G proteins in the regulation of LPS-induced signal transduction.
- G protein binding agent refers to an agent which binds to G protein and inhibits G protein signal transduction, such as a small molecule, compound, drug, polypeptide, or peptide.
- Preferred G protein binding agents bind a G ⁇ subunit.
- Particularly preferred agents are cell permeable agents.
- a particularly preferred G protein binding agent for treating bacterial sepsis is a peptide. Examples of such peptides include mastoparan and analogs thereof. Mastoparan is a permeable, amphiphilic peptide that binds Gi and Go heterotrimeric G proteins
- Mastoparan is the prototype of a family of peptide toxins, collectively known as mastoparans, that form amphiphilic alpha helices. Mastoparan has been shown to stimulate guanine nucleotide exchange by G proteins in a manner similar to that of G protein-coupled receptors.
- the mastoparans of the present invention can be naturally occurring mastoparans, or analogs thereof, which are known in the art and are described in U.S. Patent 5,589,568, incorporated herein by reference.
- Mastoparan can be synthesized and purified as described by Saito ⁇ Chem. Pharm. Bull., 32: 2187-2193, 1984) incorporated herein by reference, or alternately can be purchased from Sigma (St. Louis, MO).
- the peptides of the present invention can be prepared by standard peptide synthesis technology (e.g., Merrifield, J. Am. Chem. Soc, 88: 2149-2154, 1963;
- G protein binding agents which inhibit G protein signal transduction can be identified by their ability to inhibit the production of cytokines (such as IL-6 and TNF- ⁇ ) when cells (such as monocytes or macrophages) are contacted with the agent and a G protein stimulator, such as LPS.
- cytokines such as IL-6 and TNF- ⁇
- an agent which binds G protein can be identified by its ability to inhibit MAP kinase activation, under conditions as described herein.
- the in vivo efficacy of an agent which binds G protein and inhibits G protein signal transduction can be determined by the ability of such an agent to protect rats from LPS-induced lethal endotoxic shock as described herein.
- the present invention also pertains to compositions and methods for treating a subject having septic shock or susceptible to septic shock.
- the composition contains an effective amount of an agent which binds G protein and a pharmaceutically acceptable treatment solution.
- the present invention further pertains to the use of agents which bind G proteins together with an antibiotic for prophylactic and/or therapeutic treatments of septic shock.
- the invention also pertains to compositions for treating a subject for septic shock which include an effective amount of the antibiotic and an agent which binds G protein in a pharmaceutically acceptable carrier.
- the present invention further pertains to the use of G protein binding agents in conjunction with other agents or regimens for therapy or prophylactic treatment of septic shock.
- agents or regimens which can be administered to the subject to treat septic shock include antibiotics, intravenous fluids and cardiovascular and respiratory support.
- PBMC peripheral blood mononuclear cells
- monocytes were obtained from leukopaks (discarded leukocyte from platelet donations). The cells were fractionated on FICOLL-HYPAQUETM gradients, washed, treated with tris-buffered NH4CI to eliminate RBCs and washed to obtain PMBCs. Monocytes were obtained by depleting the PBMCs of T cells and NK cells by negative selection asking standard techniques. T cells and NK cells were removed by treatment with anti-CD3 and anti-CD2 monoclonal antibodies followed by goat anti-mouse Ig conjugated magnetic beads at a 10:1 bead:cell ratio.
- the monocyte preparations were at least 80- 85% monocytes, as determined by anti-CD 14 staining and forward and slide light scatter analysis using a FACScan (Becton-Dickenson, Elmhurst, IL). Less than 2% of the contaminating cells in the monocyte preparation were T cells and no NK cells could be detected. Monocytes were maintained in Ham's F-12 10% FCS, L-Glutamine and penacillin/streptomyocin at 37°C in 5% C0 2 .
- U373 cell CD14 transfectants (U373-CD14) were maintained in EMEM supplemented with 10% FCS, L-Glutamine and penicillin/streptomyocin at 37°C in 5% C0 2 . Immunoprecipitation, in vitro kinase assay, and reimmunoprecipitation.
- Insoluble debris was removed by microcentrifugation and the lysates were precleared with 100 ⁇ l (10% w/v) rabbit anti-mouse coated protein A sephrose beads (1 mg/ml) followed by 200 ⁇ l (10% w/v) protein A sephrose beads. The lysates were then incubated for two hours at 4°C with monoclonal antibodies previously bound to protein A sephrose beads.
- the beads were washed 4 times in lysis buffer and once in Kinase buffer [25 mM hepes, 1 mM MnCl2 and 100 ⁇ M Na3V ⁇ 4] and the immunoprecipitates were then resuspended in 50 ⁇ l kinase buffer with 20 ⁇ Ci[ ⁇ 32p]ATP (New England Nuclear, Boston, MA) and incubated for 15 minutes at room temperature.
- the samples were washed 4 times in lysis buffer with 15 mM EDTA. Samples were then eluted in 0.5%) SDS at 70°C for 3 minutes or boiled in 1% SDS for 5 minutes and diluted 10 fold with cold lysis buffer.
- Samples were analyzed by SDS -PAGE or reimmunoprecipitated with various monoclonal or polyclonal antisera (e.g., rabbit) prior to SDS-PAGE analysis.
- Reimmunoprecipitated samples were boiled in reducing Laemmli sample buffer, and subjected to electrophoresis through a 10% SDS-PAGE gel.
- Freshly isolated human monocytes, human PBMC and U373-CD14 cells were incubated with 10 ng/ml LPS (E coli 0111 :B4, Sigma, St. Louis, MO), 100 ng/ml PMA or were untreated in supplemented RPMI [10% FCS; 2 mM L-glutamine and penicillin/streptomycin] with or without various concentrations of mastoparan for 18 hours at 37°C in 24 well tissue culture dishes.
- IL-6 and TNF- ⁇ levels were determined by ELISA (Endogen Inc., Boston, MA) of supernatants harvested at 4 hours (for TNF- ⁇ ) and at 18 hours (for IL-6) after LPS stimulation.
- monocytes were subjected to various treatments and lysed in boiling reducing Laemmli sample buffer.
- the lysates were subjected to electrophoresis through a 10%) SDS PAGE gel and were then transferred to nitrocellulose (NC).
- NC nitrocellulose
- the NC was incubated with anti-p38 N + C terminus (Santa Cruz Biotechnology Inc., Santa Cruz, CA) for 2-3 hours or with anti- phosphorylated p38 and Erk antibodies (New England Biolabs, Inc., Beverly, MA) for 18 hours.
- Membranes were washed three times in TBS-Tween 20 and were incubated for 30 minutes with horseradish peroxidase conjugated donkey- ⁇ -rabbit antibody in blocking buffer (Amersham Corp., Arlington Heights, IL).
- Membranes were washed an additional six times [3 x TBS-Tween-20; 3 x TBS], and were developed by exposure to ECL chemicals (Amersham corp., Arlington Heights, IL) and visualized by exposure to film.
- Wistar rats 200 g were obtained from Charles River Laboratories. Rats were treated with 3mg/kg mastoparan by intravenous injection in the tail vein, immediately followed by 15 mg/kg lead acetate and 5 ⁇ g/kg LPS 0111 :B4 intravenously. Mortality was assessed up to 96 hours following LPS treatment. Mortality frequency was compared by Fisher exact test and statistical analysis was performed using Yates corrected Chi square test..
- Results from these assays revealed the presence of multiple tyrosine phosphorylated species which coimmunoprecipitated with CD 14 (See Figure 1 A). Reimmunoprecipitation of the product of these assays with an anti-phosphotyrosine specific antibody indicated that all the major phosphorylated species were tyrosine phosphorylated.
- CD 14 immunoprecipitates contained Gi and Go heterodimer G proteins suggests that G proteins may be involved in LPS-induced signaling.
- human cells i.e., monocytes and PBMCs
- mastoparan a cell permeable, amphiphilic peptide that binds Gi and Go heterotrimeric G proteins
- Mastoparan was a potent inhibitor of LPS-induced IL-6 production from the LPS stimulated PBMCs, while MAS- 17 had no effect on cytokine production.
- the effect of mastoparan on cytokine production was dose-dependent, and at a concentration of 13.3 ⁇ M mastoparan totally ablated LPS-induced IL-6 production from the PBMCs.
- LPS treatment of U373- CD14 transfectants induced an LPS dose-dependent production of IL-6 ( Figure 4).
- LPS-induced IL-6 responses were completely inhibited by treatment of the U373 -CD 14 cells with an anti-CD 14 monoclonal antibody.
- IL-6 production induced by 10 ng/ml LPS was also ablated by treatment of the cells with mastoparan, while at 100 ng/ml of LPS, mastoparan reduced IL-6 levels by approximately one third.
- p38 MAP kinase requires phosphorylation on both threonine and tyrosine residues (Raingeaud et al., J. BioL Chem., 270: 7420-7426, 1995). Detection of dual- phosphorylated p38 MAP kinase by monoclonal antibodies specific for the dual- phosphorylated form of p38 was used as a measure of p38 activation. Consistent with the effect of mastoparan on LPS-induced cytokine production, mastoparan reduced the LPS-induced phosphorylation of p38 MAP kinase in both monocytes and PBMC ( Figure 5A). It also inhibited LPS-induced nuclear translocation of p38.
- mastoparan may have efficacy in reducing LPS-induced pathology in vivo.
- mastoparan may have efficacy in reducing LPS-induced pathology in vivo.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU92138/98A AU9213898A (en) | 1997-09-03 | 1998-09-01 | Compositions and methods for contraception in or sterilization of mammals |
JP2000508384A JP2001514231A (en) | 1997-09-03 | 1998-09-01 | Compositions and methods for performing contraception or infertility in animals |
CA2302392A CA2302392C (en) | 1997-09-03 | 1998-09-01 | Compositions and methods for contraception in or sterilization of mammals |
US09/486,143 US6680058B1 (en) | 1997-09-03 | 1998-09-01 | Compositions and methods for contraception in or sterilization of mammals |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5745697P | 1997-09-03 | 1997-09-03 | |
US60/057,456 | 1997-09-03 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1999011282A1 true WO1999011282A1 (en) | 1999-03-11 |
WO1999011282A9 WO1999011282A9 (en) | 1999-05-14 |
Family
ID=22010643
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/018117 WO1999011282A1 (en) | 1997-09-03 | 1998-09-01 | Compositions and methods for contraception in or sterilization of mammals |
Country Status (4)
Country | Link |
---|---|
JP (1) | JP2001514231A (en) |
AU (1) | AU9213898A (en) |
CA (1) | CA2302392C (en) |
WO (1) | WO1999011282A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU23739A1 (en) * | 2008-09-30 | 2011-12-28 | Ct Ingenieria Genetica Biotech | PHARMACEUTICAL COMPOSITION USING COMBINATIONS OF VARIANTS OF THE GONADOTROPIN LIBERATING HORMONE (GNRH) AS IMMUNOGEN |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5631007A (en) * | 1990-03-12 | 1997-05-20 | Ciba-Geigy Corporation | Anti-pathogenically effective compositions comprising lytic peptides and hydrolytic enzymes |
-
1998
- 1998-09-01 AU AU92138/98A patent/AU9213898A/en not_active Abandoned
- 1998-09-01 WO PCT/US1998/018117 patent/WO1999011282A1/en active Application Filing
- 1998-09-01 CA CA2302392A patent/CA2302392C/en not_active Expired - Lifetime
- 1998-09-01 JP JP2000508384A patent/JP2001514231A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5631007A (en) * | 1990-03-12 | 1997-05-20 | Ciba-Geigy Corporation | Anti-pathogenically effective compositions comprising lytic peptides and hydrolytic enzymes |
Also Published As
Publication number | Publication date |
---|---|
CA2302392C (en) | 2012-04-10 |
CA2302392A1 (en) | 1999-03-11 |
AU9213898A (en) | 1999-03-22 |
WO1999011282A9 (en) | 1999-05-14 |
JP2001514231A (en) | 2001-09-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kettelhut et al. | The toxic effects of tumor necrosis factor in vivo and their prevention by cyclooxygenase inhibitors. | |
Marth et al. | Regulation of pp56lck during T‐cell activation: functional implications for the src‐like protein tyrosine kinases. | |
Gibot et al. | Modulation of the triggering receptor expressed on the myeloid cell type 1 pathway in murine septic shock | |
Selby et al. | Tumour necrosis factor in man: clinical and biological observations | |
Tracey et al. | Cachectin/tumor necrosis factor and other cytokines in infectious disease | |
Wang et al. | Endothelium-dependent relaxation is depressed at the macro-and microcirculatory levels during sepsis | |
US4980160A (en) | Combinations of tumor necrosis factors and anti-inflammatory agents and methods for treating malignant and non-malignant diseases | |
JP2002526117A (en) | Extracellular new RAGE binding protein (EN-RAGE) and use thereof | |
JPH09328423A (en) | Treatment of adrenal insufficiency due to aging of dog | |
Horrow | Protamine allergy | |
US5730976A (en) | Method for treating macrophage pathogen infections by TGF-B antagonists | |
US5208018A (en) | Treatment of cachexia with interleukin 2 | |
WO2001041754A9 (en) | Inhibitors of collagen-induced platelet aggregation | |
Nagler et al. | Tissue levels of acetyl choline and acetyl cholinesterase in weanling rats subjected to acute choline deficiency | |
Myers et al. | Relationships between tumour necrosis factor, eicosanoids and platelet-activating factor as mediators of endotoxin-induced shock in mice. | |
WO1996004013A1 (en) | Use of il-6 to treat toxic shock | |
US6583110B1 (en) | Use of agents which bind G proteins for treating septic shock | |
JPH09502451A (en) | Compositions and methods for stimulating platelet production using unbound MPL receptors | |
US20020151458A1 (en) | Method for treating and preventing septic shock with VPAC1R, VPAC2R and PAC1R agonists | |
WO1999011282A1 (en) | Compositions and methods for contraception in or sterilization of mammals | |
JP3538616B2 (en) | Interstitial pneumonia therapeutic agent, method for preparing animal model of the disease, and screening method using the same | |
Hoffmann et al. | In vivo effects of C3a on neutrophils and its contribution to inflammatory lung processes in a guinea-pig model. | |
Tracey et al. | Tumor necrosis factor (cachectin) in septic/endotoxic shock | |
Goldenberg et al. | New inotropic drugs for heart failure | |
Simmons et al. | Suppression of active but not passive autoimmune encephalomyelitis by dual cyclo‐oxygenase and 5‐lipoxygenase inhibition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: C2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1-15, DESCRIPTION, REPLACED BY CORRECT PAGES 1-27; PAGES 16 AND 17, CLAIMS, REPLACED BY CORRECT PAGES 28-31; PAGES 1/9-9/9, DRAWINGS, DELETED; INTERNATIONAL SEARCH REPORT REPLACED BY CORRECT INTERNATIONAL SEARCH REPORT |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 09486143 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2302392 Country of ref document: CA Ref country code: JP Ref document number: 2000 508384 Kind code of ref document: A Format of ref document f/p: F Ref country code: CA Ref document number: 2302392 Kind code of ref document: A Format of ref document f/p: F |
|
NENP | Non-entry into the national phase |
Ref country code: KR |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase |